HK1223369A1 - 用於治疗氧化应激障碍的羧酸衍生物 - Google Patents

用於治疗氧化应激障碍的羧酸衍生物 Download PDF

Info

Publication number
HK1223369A1
HK1223369A1 HK16111659.1A HK16111659A HK1223369A1 HK 1223369 A1 HK1223369 A1 HK 1223369A1 HK 16111659 A HK16111659 A HK 16111659A HK 1223369 A1 HK1223369 A1 HK 1223369A1
Authority
HK
Hong Kong
Prior art keywords
carboxylic acid
oxidative stress
compounds
treatment
acid derivatives
Prior art date
Application number
HK16111659.1A
Other languages
English (en)
Chinese (zh)
Inventor
Andrew W. Hinman
Viktoria Kheifets
William D. Shrader
Original Assignee
Bioelectron Technology Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioelectron Technology Corporation filed Critical Bioelectron Technology Corporation
Publication of HK1223369A1 publication Critical patent/HK1223369A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C66/00—Quinone carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/95—Esters of quinone carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK16111659.1A 2013-05-31 2014-05-30 用於治疗氧化应激障碍的羧酸衍生物 HK1223369A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361829886P 2013-05-31 2013-05-31
US61/829,886 2013-05-31
PCT/US2014/040387 WO2014194292A1 (en) 2013-05-31 2014-05-30 Carboxylic acid derivatives for treatment of oxidative stress disorders

Publications (1)

Publication Number Publication Date
HK1223369A1 true HK1223369A1 (zh) 2017-07-28

Family

ID=50983236

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16111659.1A HK1223369A1 (zh) 2013-05-31 2014-05-30 用於治疗氧化应激障碍的羧酸衍生物

Country Status (8)

Country Link
US (1) US20160115141A1 (https=)
EP (1) EP3004071A1 (https=)
JP (1) JP2016520621A (https=)
AU (1) AU2014273891A1 (https=)
CA (1) CA2912871A1 (https=)
HK (1) HK1223369A1 (https=)
MX (1) MX2015016014A (https=)
WO (1) WO2014194292A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2619303T3 (es) 2005-06-01 2017-06-26 Edison Pharmaceuticals, Inc. Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos
WO2007100652A2 (en) 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EA038941B1 (ru) 2007-11-06 2021-11-12 ПиТиСи ТЕРАПЬЮТИКС, ИНК. ПРОИЗВОДНЫЕ 4-(п-ХИНОНИЛ)-2-ГИДРОКСИБУТАНАМИДА ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ
US8952071B2 (en) 2008-01-08 2015-02-10 Edison Pharmaceuticals, Inc. (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases
MX363223B (es) 2008-09-10 2019-03-15 Bioelectron Tech Corp Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
ES2553557T3 (es) 2008-10-28 2015-12-10 Edison Pharmaceuticals, Inc. Proceso para la producción de alfa-tocotrienol y derivados
CA2777479C (en) 2009-04-28 2017-10-17 Ptc Therapeutics, Inc. Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
WO2012174286A1 (en) 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
EP2734512B1 (en) 2011-07-19 2019-11-20 Bioelectron Technology Corporation Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
CA2883882A1 (en) 2012-09-07 2014-03-13 Ptc Therapeutics, Inc. Benzoquinone derivatives for treating oxidative stress disorders
US10189830B2 (en) 2013-03-15 2019-01-29 Bioelectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
DK3233786T3 (da) 2014-12-16 2022-05-09 Ptc Therapeutics Inc Polymorfe og amorfe former af (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6- dioxocyclohexa-1,4-dienyl)butanamid
EP3297643A4 (en) * 2015-05-22 2019-02-06 The A2 Milk Company Limited BETA-CASEIN-A2 AND ANTIOXIDATIVE CAPACITY
US10815211B2 (en) * 2015-10-08 2020-10-27 Khondrion Ip B.V. Compounds for treating mitochondrial disease
WO2017106786A1 (en) 2015-12-16 2017-06-22 Bioelectron Technology Corporation Improved methods for enriching alpha-tocotrienol from mixed tocol compositions
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
WO2018093957A1 (en) * 2016-11-15 2018-05-24 Bioelectron Technology Corporation 2-substituted amino-naphth[1,2-d]imidazol-5-one compounds or pharmaceutically acceptable salts thereof cross reference to related applications
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
JP7266304B2 (ja) * 2017-04-21 2023-04-28 ユニヴァーシティー オブ タスマニア 治療化合物および方法
WO2019160150A1 (ja) * 2018-02-19 2019-08-22 國子 草間 バレロラクトン（Ｖａｌｅｒｏｌａｃｔｏｎｅ）系新規化合物、及び、医薬
TN2021000075A1 (en) 2018-10-17 2023-01-05 Ptc Therapeutics Inc 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING α-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS
MX2024000445A (es) 2021-07-08 2024-04-05 Ptc Therapeutics Inc Composiciones farmaceuticas que comprenden 2,3,5-trimetil-6-nonilc iclohexa-2,5-dieno-1,4-diona.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5621021B2 (https=) * 1973-12-19 1981-05-16
JPS5640651A (en) * 1979-09-12 1981-04-16 Takeda Chem Ind Ltd Quinone compound and its preparation
JPH07316049A (ja) * 1994-05-25 1995-12-05 Nippon Oil & Fats Co Ltd 細胞傷害防御剤
US6150402A (en) * 1994-08-15 2000-11-21 Loma Linda University Medical Center Natriuretic compounds
NZ513547A (en) 2001-08-13 2002-09-27 Antipodean Biotechnology Ltd Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone)
GB0204232D0 (en) 2002-02-22 2002-04-10 Isis Innovation Assay
EP1378753B1 (en) 2002-07-01 2006-05-31 Santhera Pharmaceuticals (Schweiz) GmbH A screening method and compounds for treating Friedreich Ataxia
ES2619303T3 (es) 2005-06-01 2017-06-26 Edison Pharmaceuticals, Inc. Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos
CA2883882A1 (en) 2012-09-07 2014-03-13 Ptc Therapeutics, Inc. Benzoquinone derivatives for treating oxidative stress disorders

Also Published As

Publication number Publication date
CA2912871A1 (en) 2014-12-04
MX2015016014A (es) 2016-04-04
AU2014273891A1 (en) 2015-12-24
EP3004071A1 (en) 2016-04-13
WO2014194292A1 (en) 2014-12-04
US20160115141A1 (en) 2016-04-28
JP2016520621A (ja) 2016-07-14

Similar Documents

Publication Publication Date Title
HK1223369A1 (zh) 用於治疗氧化应激障碍的羧酸衍生物
HK1220450A1 (zh) 治疗氧化应激障碍的吩嗪-3-酮和吩噻嗪-3-酮衍生产品
HK1220451A1 (zh) 用於治疗氧化应激障碍的烷基-杂芳基取代醌衍生物
HK1220449A1 (zh) 治疗氧化应激障碍的试卤灵衍生物
MX378145B (es) Formulaciones farmacéuticas tópicas que comprenden crisaborol para tratar afecciones inflamatorias
EP3413852A4 (en) METHOD, COMPOSITIONS AND DEVICES FOR TREATING PSORIASIS BY PHOTOTHERAPY
MX391378B (es) Derivados de fluoroalquil-, fluoroalcoxi-, fenoxi-, heteroariloxi-, alcoxi- y amina-1,4-benzoquinona para tratamiento de trastornos de estres oxidativo.
WO2009111576A3 (en) 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
EA201591367A1 (ru) Соединения резорцина для дерматологического применения
HK1219836A1 (zh) 用於治疗眼病的组合物、制剂和方法
IL246954A0 (en) Methods and preparations for killing aging cells and for the treatment of diseases and disorders related to aging
EP3155005A4 (en) Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
EP3347000A4 (en) METHODS OF TREATING DISORDERS AND SKIN DISORDERS USING HAPTENES
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
EP3233091A4 (en) Hypochlorous acid formulations and methods for treating skin conditions
BR112017012988A2 (pt) Formas polimoráficas e amorfas de (r)-2-hidroxi-2- metil-4- (2,4,5-trimetil-3,6-dioxociclohexa-1,4-dienil) butanamida
WO2018125800A3 (en) Metalloenzyme inhibitor compounds
EP3380471B8 (en) Tetrahydro-8h-pyrido[1,2-a]pyrazine-8-ones as comt inhibitors for the treatment of neurodegenerative disorders
EP3041577A4 (en) Treatment and prevention of autism and autism spectrum disorders
EP3052137A4 (en) Methods for the identification, assessment, prevention, and treatment of neurological disorders and diseases using fndc5
HK1223021A1 (zh) 治療和預防輻射損傷的方法
MX2016003014A (es) Extracto de filipendula vulgaris y usos del mismo.
EP3307775A4 (en) Methods for diagnosing and treating affective disorders
EA201592037A1 (ru) Экстракт cynara spp. и его применение